ProCE Banner Activity

ExpressPoints: The Evolution of Antibody–Drug Conjugates in Breast Cancer

Slideset Download

Download this short summary slideset of key takeaway points from a live presentation on new developments with antibody-drug conjugates in breast cancer.

Released: November 03, 2020

Share

Faculty

Javier Cortes

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Ian Krop

Ian Krop, MD, PhD

Associate Cancer Center Director for Clinical Research
Medical Director, Clinical Trials Office
Yale Cancer Center
Chief Scientific Officer, Translational Breast Cancer Research Consortium
New Haven, Connecticut

Prof Michael Untch

Prof Michael Untch, MD, PhD

Director of the Clinic
Gynecology, Gyencologic Oncology and Obstetrics
Helios Hospital Berlin-Buch
Berlin, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Ian Krop, MD, PhD

Associate Cancer Center Director for Clinical Research
Medical Director, Clinical Trials Office
Yale Cancer Center
Chief Scientific Officer, Translational Breast Cancer Research Consortium
New Haven, Connecticut

Ian Krop, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Lilly, Novartis, Seagen; researcher: MacroGenics.

Prof Michael Untch, MD, PhD

Director of the Clinic
Gynecology, Gyencologic Oncology and Obstetrics
Helios Hospital Berlin-Buch
Berlin, Germany